Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.

Rich P, Mitchell RB, Schaefer E, Walker PR, Dubay JW, Boyd J, Oubre D, Page R, Khalil M, Sinha S, Boniol S, Halawani H, Santos ES, Brenner W, Orsini JM, Pauli E, Goldberg J, Veatch A, Haut M, Ghabach B, Bidyasar S, Quejada M, Khan W, Huang K, Traylor L, Akerley W

Open source

DOI: 10.1136/jitc-2021-002989
Published: 2021 Oct
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2021-002989,
  title = {Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.},
  author = {Rich P and Mitchell RB and Schaefer E and Walker PR and Dubay JW and Boyd J and Oubre D and Page R and Khalil M and Sinha S and Boniol S and Halawani H and Santos ES and Brenner W and Orsini JM and Pauli E and Goldberg J and Veatch A and Haut M and Ghabach B and Bidyasar S and Quejada M and Khan W and Huang K and Traylor L and Akerley W},
  year = {2021},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2021-002989},
  url = {https://doi.org/10.1136/jitc-2021-002989}
}

RIS

TY  - JOUR
TI  - Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.
AU  - Rich P
AU  - Mitchell RB
AU  - Schaefer E
AU  - Walker PR
AU  - Dubay JW
AU  - Boyd J
AU  - Oubre D
AU  - Page R
AU  - Khalil M
AU  - Sinha S
AU  - Boniol S
AU  - Halawani H
AU  - Santos ES
AU  - Brenner W
AU  - Orsini JM
AU  - Pauli E
AU  - Goldberg J
AU  - Veatch A
AU  - Haut M
AU  - Ghabach B
AU  - Bidyasar S
AU  - Quejada M
AU  - Khan W
AU  - Huang K
AU  - Traylor L
AU  - Akerley W
PY  - 2021
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2021-002989
UR  - https://doi.org/10.1136/jitc-2021-002989
ER  -

APA

P, R., RB, M., E, S., PR, W., JW, D., J, B., D, O., R, P., M, K., S, S., S, B., H, H., ES, S., W, B., JM, O., E, P., J, G., A, V., M, H., B, G., S, B., M, Q., W, K., K, H., L, T., & W, A. (2021). Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2021-002989

Source records

pubmed · retrieved 2026-09-25T05:50:48.108Z